Market Overview

IntelliPharmaCeutics Spikes Over 12% Higher on Settlement for Generic Version of Effexor


IntelliPharmaCeutics (NASDAQ: IPCI) spikes over 12% higher on the settlement for a generic version of Effexor.

The company was granted a non-exclusive license to the patents in suit that will permit Intellipharmaceutics to launch a generic of Effexor XR in the United States following U.S. Food and Drug Administration approval of this product.

IntelliPharmaCeutics is currently trading at $3.85 per share.

Posted-In: Intraday Update


Related Articles (IPCI)

Get Benzinga's Newsletters